Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma

Blood Cancer J. 2023 Feb 13;13(1):25. doi: 10.1038/s41408-023-00796-9.

Sridurga Mithraprabhu^{1

2}, John Reynolds^{3

4}, Rose Turner⁴, Hang Quach⁵, Noemi Horvath⁶, Ian Kerridge⁷, Anna Kalff⁴, Krystal Bergin^{3

4}, Jay Hocking⁴, Flora Yuen⁴, Tiffany Khong^{3

4}, Brian M Durie⁸, Andrew Spencer^{9

10}

¹ Australian Centre for Blood Diseases, Alfred Health-Monash University, Melbourne, VIC, Australia. Durga.mithraprabhu@monash.edu.
² Department of Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, VIC, Australia. Durga.mithraprabhu@monash.edu.
³ Australian Centre for Blood Diseases, Alfred Health-Monash University, Melbourne, VIC, Australia.
⁴ Department of Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, VIC, Australia.
⁵ St.Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.
⁶ Royal Adelaide Hospital, Adelaide, SA, Australia.
⁷ Royal North Shore Hospital, Sydney, NSW, Australia.
⁸ Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA.
⁹ Australian Centre for Blood Diseases, Alfred Health-Monash University, Melbourne, VIC, Australia. Andrew.spencer@monash.edu.
¹⁰ Department of Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, VIC, Australia. Andrew.spencer@monash.edu.

No abstract available

Publication types